Overview

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

Status:
COMPLETED

Trial end date:
2025-07-04

Target enrollment:

Participant gender:

Summary

A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE50-0134 administered orally in healthy volunteers.

Phase:

PHASE1

Details

Lead Sponsor:

Eilean Therapeutics

Treatments:

Itraconazole
Rabeprazole